Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Free Report) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 17,399 shares, a decrease of 84.8% from the June 30th total of 114,234 shares. Based on an average daily volume of 41,300 shares, the short-interest ratio is presently 0.4 days. Currently, 1.2% of the company’s stock are short sold.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in GNOM. Bank of America Corp DE raised its position in shares of Global X Genomics & Biotechnology ETF by 67.8% during the 1st quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after acquiring an additional 48,394 shares in the last quarter. Wealth Management Partners LLC purchased a new position in Global X Genomics & Biotechnology ETF in the first quarter valued at approximately $244,000. Creative Financial Designs Inc. ADV raised its holdings in Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after purchasing an additional 481 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $575,000. Finally, IFP Advisors Inc lifted its position in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after buying an additional 489 shares during the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.
Global X Genomics & Biotechnology ETF Price Performance
Shares of Global X Genomics & Biotechnology ETF stock traded down $0.98 during trading on Friday, hitting $53.92. 13,696 shares of the stock were exchanged, compared to its average volume of 15,486. The stock has a market cap of $78.72 million, a price-to-earnings ratio of -23.04 and a beta of 1.16. The firm’s 50-day moving average price is $52.16 and its 200 day moving average price is $48.19. Global X Genomics & Biotechnology ETF has a 12-month low of $34.04 and a 12-month high of $59.48.
Global X Genomics & Biotechnology ETF Dividend Announcement
About Global X Genomics & Biotechnology ETF
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.
Featured Stories
- Five stocks we like better than Global X Genomics & Biotechnology ETF
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
